Abstract: An example telepresence terminal includes a display, an image sensor, an infrared emitter, and an infrared depth sensor. The terminal may determine image data using visible light emitted by the infrared emitter and captured by the image sensor and determine depth data using infrared light captured by the infrared depth sensor. The terminal may also communicate the depth data and the image data to a remote telepresence terminal and receive remote image data and remote depth data. The terminal may also generate a first display image using the lenticular display based on the remote image data that is viewable from a first viewing location and generate a second display image using the lenticular display based on the remote image data and the remote depth data that is viewable from a second viewing location.

Abstract: Provided herein are scaffolds (e.g., synthetic meshes) having optimized material properties (e.g., initial stiffness, tensile strength) and related uses thereof (e.g., use in cardiac medical procedures).

Abstract: The present invention is directed to a method of assessing in vivo human glial cell response to pathogenic infection that involves providing a non-human mammal either with at least 30% of its glial cells in its corpus callosum being human glial cells and/or with at least 5% of its glial cells its brain and brain stem white matter being human glial cells, subjecting the non-human mammal to pathogenic infection and assessing the in vivo human glial cell response to pathogenic infection. A method of identifying therapeutic agents for the pathogenic infection as well as forms of the non-human mammal having a pathogenic brain infection are also disclosed.

Abstract: An example telepresence terminal includes a lenticular display, an image sensor, an infrared emitter, and an infrared depth sensor. The terminal may determine image data using visible light emitted by the infrared emitter and captured by the image sensor and determine depth data using infrared light captured by the infrared depth sensor. The terminal may also communicate the depth data and the image data to a remote telepresence terminal and receive remote image data and remote depth data. The terminal may also generate a first display image using the lenticular display based on the remote image data that is viewable from a first viewing location and generate a second display image using the lenticular display based on the remote image data and the remote depth data that is viewable from a second viewing location.

Abstract: The present disclosure is directed to a method of treating a neuropsychiatric disorder. This method involves selecting a subject having the neuropsychiatric disorder and administering to the selected subject a preparation of glial progenitor cells at a dosage effective to treat the neuropsychiatric disorder in the subject. Another aspect of the disclosure is directed to a method of treating a neuropsychiatric disorder that includes selecting a subject having the neuropsychiatric disorder and administering, to the selected subject, a potassium (K+) channel activator at a dosage effective to restore normal brain interstitial glial K+ levels in the selected subject and treat the neuropsychiatric disorder is also disclosed.

Abstract: The present invention provides compositions and methods for improving cardiac function. Specifically, the present invention provides compositions and methods for treating a subject having a disorder or condition associated with aberrant cardiac tissue function, comprising contacting a patient having a disorder or condition associated with aberrant cardiac tissue function with a construct, or a construct associated with therapeutic cells, or a construct associated with fibroblast cells and therapeutic cells.

Abstract: An integrated additive manufacturing system includes: (a) at least one resin supply (41); (b) a plurality of additive manufacturing machines (43) on which parts may be produced, each of the additive manufacturing machines (43) operatively associated with the at least one resin supply (41); and (c) at least one peripheral machine (200, 48, 220) operatively associated with each of the additive manufacturing machines and the at least one resin supply.

Abstract: The present disclosure relates to methods of producing a preparation of CD140a/PDGFR? positive cells from pluripotent cells, where the preparation comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFR?. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM? sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of enriching and therapeutic uses of the disclosed cell preparation are also described.

Abstract: The present disclosure relates to a preparation of CD140a/PDGFR? positive cells that comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFR?. The preparation of cells is derived from pluripotent cells that were derived from skin cells, fibroblasts, umbilical cord blood, peripheral blood, bone marrow, or other somatic cells. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM? sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of making, isolating and using the disclosed cell preparation are also described.

Abstract: The present disclosure relates to a preparation of CD140a/PDGFR? positive cells that comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFR?. The preparation of cells is derived from pluripotent cells that were derived from skin cells, fibroblasts, umbilical cord blood, peripheral blood, bone marrow, or other somatic cells. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM? sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of making, isolating and using the disclosed cell preparation are also described.

Abstract: An integrated additive manufacturing system includes: (a) at least one resin supply (41); (b) a plurality of additive manufacturing machines (43) on which parts may be produced, each of said additive manufacturing machines (43) operatively associated with said at least one resin supply (41); and (c) at least one peripheral machine operatively associated with each of said additive manufacturing machines and said at least one resin supply, wherein said at least one peripheral machine comprises a part fixturing apparatus (200).

Abstract: The present invention relates to a method of modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist or antagonist of one or more molecules set forth in Tables 1 and/or 2 to the neural progenitor cells. Also disclosed is a method of using an inhibitor of sterol synthesis to differentiate oligodendrocyte progenitor cells to oligodendrocytes.

Abstract: The present disclosure relates to a preparation of CD140a/PDGFR? positive cells that comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFR?. The preparation of cells is derived from pluripotent cells that were derived from skin cells, fibroblasts, umbilical cord blood, peripheral blood, bone marrow, or other somatic cells. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM?sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of making, isolating and using the disclosed cell preparation are also described.

Abstract: An example telepresence terminal includes a lenticular display, an image sensor, an infrared emitter, and an infrared depth sensor. The terminal may determine image data using visible light emitted by the infrared emitter and captured by the image sensor and determine depth data using infrared light captured by the infrared depth sensor. The terminal may also communicate the depth data and the image data to a remote telepresence terminal and receive remote image data and remote depth data. The terminal may also generate a first display image using the lenticular display based on the remote image data that is viewable from a first viewing location and generate a second display image using the lenticular display based on the remote image data and the remote depth data that is viewable from a second viewing location.

Abstract: An adhesive pressure bandage for treating a wound or reduce scarring of a skin of a patient, the pressure bandage including a pressure member made of an elastic material. The pressure member comprising a curved central portion and two end portions. The pressure member also having two sides, an inner surface facing towards the patient and an outer surface facing away from the patient, and between the inner surface and the skin of the patient is an adhesive to attach the pressure member to the skin of the patient. Between the inner surface of the pressure member and the skin of the patient is a treatment device that is in contact with the wound, after the adhesive pressure bandage is applied to the skin of the patient, this treatment device is located between a central portion of the pressure member and the wound.

Abstract: An example telepresence terminal includes a lenticular display, an image sensor, an infrared emitter, and an infrared depth sensor. The terminal may determine image data using visible light emitted by the infrared emitter and captured by the image sensor and determine depth data using infrared light captured by the infrared depth sensor. The terminal may also communicate the depth data and the image data to a remote telepresence terminal and receive remote image data and remote depth data. The terminal may also generate a first display image using the lenticular display based on the remote image data that is viewable from a first viewing location and generate a second display image using the lenticular display based on the remote image data and the remote depth data that is viewable from a second viewing location.

Abstract: Disclosed herein are contractile cell constructs, methods for using them to treat disease, and methods for making them.

Abstract: The present application relates to a non-human mammal model of a human neurodegenerative disorder, methods of producing the non-human mammal model, and methods of using the non-human mammal model to identify agents suitable for treating a neurodegenerative disorder. The present application also relates to methods of treating neurodegenerative disorders and restoring normal brain interstitial potassium levels.

Abstract: One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types.

Abstract: Systems are provided for assessing the likelihood that a sample of cardiac tissue will spontaneously exhibit disordered electrical activity. These systems induce ventricular tachycardia or other disordered electrical activity in a sample of human and/or animal cardiac tissue either in vivo or in vitro. This system can be used to assess the ability of various pharmaceuticals, genetic modifications, electrical pacing, surgical ablation, or other therapeutic interventions to prevent or halt such disordered electrical activity. This system detects electrical activity from a plurality of points on the surface of the sample of cardiac tissue and generates one or more maps of monophasic action potential amplitude, monophasic action potential duration, local field amplitude, or other electrophysiological parameters of the cardiac tissue.